A high 18F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas.

about

A high 18F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas.

Item

http://www.wikidata.org/entity/Q47560753

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A high 18F-FDOPA uptake is ass ...... diffuse Grade II-III gliomas.

@en

A high 18F-FDOPA uptake is ass ...... diffuse Grade II-III gliomas.

@nl

type

Item

label

A high 18F-FDOPA uptake is ass ...... diffuse Grade II-III gliomas.

@en

A high 18F-FDOPA uptake is ass ...... diffuse Grade II-III gliomas.

@nl

prefLabel

A high 18F-FDOPA uptake is ass ...... diffuse Grade II-III gliomas.

@en

A high 18F-FDOPA uptake is ass ...... diffuse Grade II-III gliomas.

@nl

P1476

A high 18F-FDOPA uptake is ass ...... n diffuse Grade II-III gliomas

@en

P2093

Fabien Rech

http://www.w3.org/2001/XMLSchema#string

Gilles Karcher

http://www.w3.org/2001/XMLSchema#string

Guillaume Gauchotte

http://www.w3.org/2001/XMLSchema#string

Luc Taillandier

http://www.w3.org/2001/XMLSchema#string

Marie Blonski

http://www.w3.org/2001/XMLSchema#string

Mohammad B Chawki

http://www.w3.org/2001/XMLSchema#string

Pierre-Yves Marie

http://www.w3.org/2001/XMLSchema#string

Sibel Isal

http://www.w3.org/2001/XMLSchema#string

Sophie Planel

http://www.w3.org/2001/XMLSchema#string

P2860

The 2007 WHO classification of tumours of the central nervous system

New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach.

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.

Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas.

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH.

FDOPA PET-CT of Nonenhancing Brain Tumors.

Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET.

IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.

P304

20170803

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1259/BJR.20170803

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

1084

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antoine Verger

P577

2018-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29271237

http://www.w3.org/2001/XMLSchema#string

P932

5965991

http://www.w3.org/2001/XMLSchema#string